[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=2acf64cf3ef77ff652a0b0ec087b61ef3414a9d056577b55f8fa93c58b1b1689",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731429300,
      "headline": "Merck & Co. Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131414229,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=2acf64cf3ef77ff652a0b0ec087b61ef3414a9d056577b55f8fa93c58b1b1689"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 300-point fall led by losses in shares of Amgen, 3M",
    "summary": "Dow's 300-point fall led by losses in shares of Amgen, 3M",
    "url": "https://finnhub.io/api/news?id=a5251fadb7e9004bb567cb954e154ae8f24b932d0832764f4146d7e2545db7cf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731425160,
      "headline": "Dow's 300-point fall led by losses in shares of Amgen, 3M",
      "id": 131414230,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 300-point fall led by losses in shares of Amgen, 3M",
      "url": "https://finnhub.io/api/news?id=a5251fadb7e9004bb567cb954e154ae8f24b932d0832764f4146d7e2545db7cf"
    }
  },
  {
    "ts": null,
    "headline": "Merck trial shows Koselugo effective in treating adults",
    "summary": "Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase 3 Komet trial shows statistically significant and clinically...",
    "url": "https://finnhub.io/api/news?id=d77c275332428f36f40137d530601c2f525a74e6b00b29519ef94d60f77059ff",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731423133,
      "headline": "Merck trial shows Koselugo effective in treating adults",
      "id": 131309938,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase 3 Komet trial shows statistically significant and clinically...",
      "url": "https://finnhub.io/api/news?id=d77c275332428f36f40137d530601c2f525a74e6b00b29519ef94d60f77059ff"
    }
  },
  {
    "ts": null,
    "headline": "With 79% ownership, Merck & Co., Inc. (NYSE:MRK) boasts of strong institutional backing",
    "summary": "Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...",
    "url": "https://finnhub.io/api/news?id=cb27131765add4ee47af1112c8e4692c56a64d9df4be4e6665b341ef63e8714a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731412814,
      "headline": "With 79% ownership, Merck & Co., Inc. (NYSE:MRK) boasts of strong institutional backing",
      "id": 131304284,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...",
      "url": "https://finnhub.io/api/news?id=cb27131765add4ee47af1112c8e4692c56a64d9df4be4e6665b341ef63e8714a"
    }
  },
  {
    "ts": null,
    "headline": "KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial",
    "summary": "RAHWAY, N.J., November 12, 2024--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs",
    "url": "https://finnhub.io/api/news?id=b9d618a7cbd37420d0d3c068f1d25f6033b48e944216619b70c2ce84f90d8349",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731411900,
      "headline": "KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial",
      "id": 131304287,
      "image": "https://media.zenfs.com/en/business-wire.com/8ade5f8d098303e188d4628cb037b75a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 12, 2024--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs",
      "url": "https://finnhub.io/api/news?id=b9d618a7cbd37420d0d3c068f1d25f6033b48e944216619b70c2ce84f90d8349"
    }
  },
  {
    "ts": null,
    "headline": "Merck: promising results from Koselugo study",
    "summary": "Alexion, AstraZeneca's rare disease company, and Merck announce positive results from the Phase 3 clinical trial of Koselugo in adult patients with neurofibromatosis type 1 with symptomatic...",
    "url": "https://finnhub.io/api/news?id=d505561060259e0c7eef089dc646b783ad857c1d43fa8a41d039e49defc716ac",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731410652,
      "headline": "Merck: promising results from Koselugo study",
      "id": 131306247,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Alexion, AstraZeneca's rare disease company, and Merck announce positive results from the Phase 3 clinical trial of Koselugo in adult patients with neurofibromatosis type 1 with symptomatic...",
      "url": "https://finnhub.io/api/news?id=d505561060259e0c7eef089dc646b783ad857c1d43fa8a41d039e49defc716ac"
    }
  },
  {
    "ts": null,
    "headline": "Merck: new data on HPV vaccine",
    "summary": "Merck announces that new clinical and real-world data on its 9-valent human papillomavirus vaccine, 'Gardasil 9', will be presented at the International Papillomavirus Conference 2024 in Edinburgh....",
    "url": "https://finnhub.io/api/news?id=7b076fa119146b5762860c594555043d158ccacad9b4b6c083817d2b2c4c7438",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731410191,
      "headline": "Merck: new data on HPV vaccine",
      "id": 131306181,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that new clinical and real-world data on its 9-valent human papillomavirus vaccine, 'Gardasil 9', will be presented at the International Papillomavirus Conference 2024 in Edinburgh....",
      "url": "https://finnhub.io/api/news?id=7b076fa119146b5762860c594555043d158ccacad9b4b6c083817d2b2c4c7438"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024",
    "summary": "RAHWAY, N.J., November 12, 2024--Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at IPVC 2024.",
    "url": "https://finnhub.io/api/news?id=e015c0802b573379da513232ca90afbae9d2ba6cc66beb9e1a30fedfb05ff95d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731398400,
      "headline": "Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024",
      "id": 131304289,
      "image": "https://media.zenfs.com/en/business-wire.com/d3aec629ab72a2f1fd14b0d31d6767f3",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 12, 2024--Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at IPVC 2024.",
      "url": "https://finnhub.io/api/news?id=e015c0802b573379da513232ca90afbae9d2ba6cc66beb9e1a30fedfb05ff95d"
    }
  }
]